GSK and Summit Therapeutics Partner for Cancer Treatment Trial

GSK has partnered with Summit Therapeutics to explore a new cancer treatment strategy. The collaboration will test the combination of ivonescimab and GSK's B7-H3 targeting antibody drug conjugate across various solid tumors. The trial aims to commence patient dosing by mid-2026, with both companies retaining rights to their respective products. The partnership aims to accelerate ivonescimab's development across multiple solid tumor types.